CASE STUDIES
BRAIN AND NEURAL TISSUE
Glioblastoma
Male patient (44); on DDW from 12-05-1995
In August 1995, a left temporoparietal tumor histologically defined as glioblastoma had been removed, after which the patient was given radiotherapy. In January 1996, half a year after surgery, CT scan verified the growth of the ring-like accretion in the operated area. In April 1996, after the patient had been given contrast material, an inhomogeneous contrast accretion was observed along with a slight progression of the remaining tumor. In October 1997, CT scan raised the suspicion of a solid recidiva, 1 cm in diameter. In April 1997, the temporoparietal tumor was approx. 3 cm, and the expansive character increased. In 1997, chemotherapy was given. The patient died after 2 years’ survival in November 1997.
Neurofibromatosis
Female patient (12); on DDW from 08-06-1996
The young girl had been treated with opticus glioma, caused by neuro-fibromatosis, and resulting in amaurosis on both sides. In August 1994, the basic condition caused multiple lesions of the central nervous system, accompanied by decreased hearing, facial, oculomotoric, abducent paresis, and the paralysis of the upper and lower right limbs. Carboplatin/VP-16 chemotherapy was given, and, to assess efficacy, MRI was also carried out. According to the MRI, a significant expansion occurred and examinations verified progression. Following this, the patient was given no other conventional treatment. The girl first began to consume, in January 1996, the 130-ppm preparation called Vitaqua available at that time. Then, from August, she started to drink an 85-ppm preparation. According to the MRI made in November 1996, the size and contrast matter accumulation of the formerly described focus significantly decreased and the regression of the tumor was verified. Since the start of DDW consumption, the girl’s ability to speak and move has constantly been improving. In January 1997 she was able to walk unaided. In August 1997, contrasted to the state in November 1996, the tumor’s size was half of the original. MRI made in December 1998 showed no progression either. The girl has been continuing her studies for more than two years now.
Neuroepithelioma
Male patient (45); on DDW from 04-25-1995
Severe pain in the back of the patient had appeared in November 1994, upon which L. II–V. compr. fracture was verified but the origin of the primary tumor was impossible to define. A CT scan in March 1995 revealed significant progression, which was most expressed at the level of the L. IV. vertebra. Compared to the previous examination, the body of the vertebra was narrower by 0.5 cm. A process of a soft tissue density, destroying nearly the whole body of the vertebra and the right side proc. transversus was spreading towards the spinal canal. Biopsy verified neuroepthelioma. Because of its range and location, the tumor was inoperable. Prior to Dd-water consumption the patient had been bed-ridden. His pain increased somewhat 6-7 days after the beginning of the cure, but 3 weeks later no morphine was needed and the patient was able to get up. Three months later the patient was able to walk by himself without using a cane and was also able to drive a car. He had been consuming DDW until August 1995; we have no further information since that time.
Astrocytoma
Male patient (29); astrocytoma A3; on DDW from 03-28-1995
Following epileptic bouts from 1991, examinations verified the presence of a brain tumor. The operation took place in January 1995. The patient consumed DDW for 44 months without interruption. During recent years, seizures which had been frequent and strong in the beginning gradually decreased. In the past months, several weeks passed without seizures or, if they happened at all, they were very mild. Then, after 4 years, from March 1999 on, the former 62-ppm preparation was substituted for a 100-ppm one. After one month, strong headache appeared, and after another month a quick deterioration was observed. MRI verified the appearance of a tumor and cyst the size of a fist. A further increased dose of DDW was not able to inhibit tumor growth. The patient later underwent an operation to remove the tumor.
The case is a good example of the significant role of DDW in the inhibition of tumor growth. The dose had been appropriate for 42 months, but even after 4 years neither the increase of the D-content of DDW, nor the decrease of the dose were justified, as within two months the patient relapsed.
BREAST
Female patient (47) on DDW from 1-28-2004
The patient underwent surgery first in July 2002 when a tumour of the breast with a size of 10x8x6 mm was excised then radiotherapy was applied. Despite the continuous medication (Zitazonium, Zoladex) a metastasis was detected to her rib by bone scintigraphy. The patient started to consume DDW 2 months after the detection of distant metastasis and consumed it continuously for 15 months. During this period the two examinations with bone scintigraphy did not show any progression of the disease. In the fall of 2007 the patient was asymptomatic, her findings (mammography, chest X-ray, tumour marker) were negative in the years past.
Female patient (58) on DDW from 2-15-2002
The patient underwent a total mastectomy in September 1992. CT-scan detected a lung metastasis of 7.5×5.5×2.5 cm size in January 2002. The patient started consuming DDW 1 month later parallel with chemotherapy. Eight months later the PET examination could not show the metastasis. PET detected 3 different lymph nodes of pathologic size in August 2004 that was treated with cytostatic medication and Herceptin. In November, the enlarged lymph nodes could not be detected by the control CT-scan. Patient was continuously consuming DDW with smaller interruptions and was asymptomatic in the summer of 2007, more than 5 years after the detection of a large-sized distant metastasis.
Female patient (62) on DDW from 4-01-2002
Breast cancer was diagnosed in October 1998. The patient had been already experiencing the introversion of her nipple for years. She rejected the surgical intervention, in the same way chemo-, and radiotherapy. She experienced a pain in her hip and a referred leg pain in November 2001. Because of the severe pain she was unable to walk, so she had become bed-ridden. DDW-treatment was started in January 2002. The consistency of the tumour previously having a cartilage hardness touch became softer in February. She was given radiotherapy because of the osteal process in the lumbar region, but she also continued the consumption of DDW. She took a higher dose of DDW from July. She was able to walk with a stick without any analgetics in October 2002 and could manage the household by January 2003. In spring, the bone scintigraphy showed the decrease of the size and number of the bone metastases. The patient gained 8 kg in body weight. She was leading an active life and was doing gardening. She died in June 2004, 2 ½ years after the start of DDW-treatment in a bed-ridden condition.
Female patient (46); on DDW from 07-12-1993
After the diagnosis of breast cancer in 1988, bone metastasis was verified in September 1992 for the first time. Until the patient started drinking DDW, examinations verified progression, and her pains and disability increased. Following the administration of DDW, her pains subsided within 1–1.5 months, and bone scintigraphy conducted two months later could not verify several smaller metastases that had earlier been present. The patient consumed DDW until January 1994 and noted an improvement in the quality of life. She then suspended the consumption of DDW. After four months she experienced significant deterioration, and her pains reappeared. Bone scintigraphy, performed in September 1994, verified moderate progression. After this the patient decided to resume the therapy. Bone scintigraphy in October 1995 could not reveal further metastases. Despite the above, there was a slow progression, while in the first three years of consuming DDW her quality of life did not change significantly. In December 1996, due to metastases, she suffered a pathological fracture in her upper arm, and her thighbones were surgically reinforced. The upper arm bone knitted, in the summer of 1997 the patient regained 10 kg of the lost body weight and her pains were controllable with drugs. During the first four years of treatment, no metastasis occurred in the soft tissues. CT scanning in October 1997 revealed brain metastasis. The patient died five and a half years after the appearance of the bone metastasis; she had been consuming DDW for four and a half years.
Female patient (39); on DDW from 09-03-1994
The patient underwent surgery first in 1986, when a walnut-sized tumor, which had been present for a year was removed. The first recidiva appeared in 1987. The suspicion of bone metastasis came up in September 1993, verified by examinations in March 1994. The illness progressed despite intense conventional treatment. Shortly before the start of Dd-water consumption the following is to be read in her final report: “St. P. amput. Mammae l. d. pp. Cc. Metastasis localis cutis. Metastasis ossis capitis. Metastasis vertebrae C. III. proc. Spin. Th. Iv. VII. VIII. IX. XII: L. I. II. III. Metastasis pulm. L. s. Metastasis costae V. l. d. ilei l. d. Laesio plexus brachialis l. d. Anaemia sec. St. P. ovariectomiam…” Because of her severe pain, the patient needed morphine. Some weeks after the start of the cure she no longer needed painkillers. In October, a tumor under her nose became flatter and smaller in size. X-ray examination in November verified the regression of the lung metastasis. Bone scintigraphy in March 1995 also showed regression. In January 1996 an examination stated full regression in the lung, with further regression in the bones. Metastases under the skin of the head further progressed from November 1996. By January 1997, the lungs were clear and the patient reported no pain. She drank DDW until the spring of 1998 and after a half-year break she resumed the consumption of DDW in November 1998. Subsequent bone scintigraphy described minimal metastases at some points only. The patient has been free from pain for five years. Since the beginning of the DDW therapy, her quality of life is good and she leads an active life.
Female patient (72); on DDW from 03-11-1994
The patient underwent breast surgery in 1985. At the end of 1993, examinations verified metastases in the brain, liver, and bones. She had been consuming DDW from the above date until her death in May 1996. In contrast to the expected 2–3 month of survival, she lived for 26 months in a stable and fairly good general condition.
Female patient (39); on DDW from 08-23-1993
Following surgery in October 1991, the patient received CMF–radiotherapy–CMF treatment. In July 1993, block-dissection was performed on her right armpit. She had been consuming DDW between August and November 1993. In the fall of 1994 she complained about double sight and CT scan verified an affected area in the temporal region. From December 1994, she had been consuming DDW irregularly, not in the recommended quantities. In the spring of 1995, mediastinary and pulmonary affection was verified. The patient resumed the consumption of DDW between March and September 1995, later stopping and starting again in October 1996. She has been drinking DDW continuously ever since. Her state reflected stagnation, progression and improvement alike. The patient is still alive (May 1999), despite her diagnosis of brain metastasis and lung metastasis five years earlier.
Female patient (56); on DDW from 01-10-1995
In August 1990 the patient underwent mamma exstirpatio, histology proved invasive cc. mammae. After surgery the patient was given radiotherapy. In 1992, metastasis appeared in her left breast, too. Prior to the consumption of Dd-water, examinations verified metastases in the ribs and in the L. II–III–IV vertebrae. The patient had severe back pain. Three months after the start of the DDW cure, her complaints eased, and her general condition improved. Blood counts of June 1995 showed considerably better results, ESR value instead of the former 60 decreased to 26, and no purulence appeared in the urine. By October the condition of the patient had further improved and she was gaining weight. Influenza in February 1996 retarded improvement for a long time. In August, examinations confirmed a metastasis in the brain. As a consequence of both DDW and conventional treatment, intermittent improvement and worsening followed until June 1997, at which time patient died. There was a clear improvement after the consumption of DDW, and a 30 months survival after the appearance of bone metastasis and 10 months survival after the diagnosis of brain metastasis.
Female patient (42); on DDW from 05-18-1995
Following breast surgery in April 1993, the patient received radiotherapy. In March 1995, local recidiva appeared as well as bone metastases in the vertebrae and the sternum. The patient began consuming DDW two months later, and continued consuming it for 42 months. Bone scintigraphy conducted in December 1995 showed no progression. The pains subsided and the general state of the patient improved. Throughout 1996 good general health was observed. In January 1997 pulmonary edema appeared, but apart from occasional pain in her sacrum, the patient felt well. A X-ray scan performed in October 1997 reinforced suspicion of lung damage but the former ovarian cyst could not be verified. In January 1998 the patient began to cough, and examinations verified lung metastasis, after which the cytostatic treatment of the patient began.
Female patient (48); on DDW from 08-28-1995
Because of invasive lobular cc, in the summer of 1986, sectoral excision was performed on the left breast with axillar block dissection. After surgery the patient was given radiotherapy but she would not accept accompanying chemotherapy. In 1990 recidiva were removed from the left breast, followed by radiotherapy. In August 1995, wide inoperable recidiva appeared infiltrating the whole breast. Then a combined cytostatic treatment began after the CMF-scheme. The consumption of DDW also started in August 1995. The subsequent regression was more than 50 percent. After finishing chemotherapy regression continued. The patient has been drinking DDW since August 1995, is free of complaints and has returned to work.
Female patient (37); on DDW from 02-26-1996
The patient’s breast tumor had first been operated on in 1993, after which she was given radiotherapy. A bone scintigraphy performed in 1995 verified metastasis; chemotherapy begun afterwards lasted until October 1996. Because of the cytostatic treatment the patient consumed DDW irregularly between February and August 1996, but despite several breaks in the cure, she has been consuming it regularly since August 1996. In the period between August and October 1996, the patient gained 3 kg of weight, and needed no help walking. She has been active ever since and has no pain. According to a 1998 check-up, the process has consolidated; a significant calcification was verifiable in the bones. The constriction in the hips has loosened; the patient tolerates significant physical stress (swimming, mountain climbing) and is in good general condition.
Female patient (48); on DDW from 11-19-1996
Anamnesis indicated a right side breast ablation, because of a tumor in the T2N0M0 state. The patient also received radio-chemotherapy during surgery. In August 1996 pleural and lung metastases were verified. Cytostatic treatment started according to the MMM scheme, from which 4 series were administered until the start of the DDW therapy. Routine examinations did not reveal any changes in the size of the tumor. The patient started to consume DDW at this point. By January 1997, the size of lung metastases diminished considerably, with the patient gained weight. According to the CT scan of March 1997, a significant regression took place in the lung. In August 1997 complete regression was reported, and MMM treatment finished. In the fall of 1997, the patient was able to travel abroad and gave a course outside the country. The X-ray examination of October showed further improvement, a residual tumor remained in the pleura only. An examination of February 1997 gave a negative result. In July 1998, a progression of the metastases in the pleura was observable. Taxotere treatment began in August 1998 and finished in November.
Female patient (54); on DDW from 03-18-1997
The patient underwent her first operation in 1983, during which the involvement of the lymphatic nodes was verified. In 1992, after an epileptic seizure, metastasis in the brain was revealed. After surgery the patient was given chemotherapy and radiation. In August 1996, metastases in the lungs appeared. CT scan in March 1997 revealed, besides the metastasis in the lungs, metastasis of the liver and adrenal gland as well. In August 1997, five months after the beginning of the DDW therapy, the liver metastasis was stagnating. In October it showed regression, and in June 1998, complete tumor regression was verified. The abdominal sonography in October revealed a negative result with regard to both the liver and adrenal gland. By the end of 1997 deterioration was experienced, and the patient was given radiotherapy followed by two doses of cytostatic treatment. Since April 1998, the patient has been in good physical state with no complaints. During the summer she coughed up considerable amounts of a white jelly-like secretion which is a characteristic phenomenon following DDW consumption involving of the lungs.
LUNG CANCER
Note: With regard to the frequent occurrence of lung cancer, we have described several cases. It is clear from the above that we were able to provide positive examples to demonstrate all types of lung cancers. If we were to make a statistical summary, we would see that in 60–70 percent of the cases there was an objective reaction after the consumption of DDW; survival rates increased significantly and the tumor could, for years, remain dormant. The case of the 75-year-old patient illustrates well that in remission following surgery, DDW can prevent later recurrence, which would supposedly have happened taking tumor marker values into consideration. Results can significantly be improved by beginning the treatment with 75–85-ppm DDW instead of 90-ppm water. This is justified especially in the case of large (4–5 cm) tumors.
Male patient (62); on DDW from 04-21-1993
The condition was diagnosed in 1992; thoracotomy verified an inoperable tumor. After the diagnosis, the patient was given radiotherapy and first consumed DDW regularly between April 1993 and September 1993. During this time no progression could be traced. Later the patient gave up the cure because of the pain that appeared 5–10 minutes after drinking the water. Following this the patient lost 15 kg until 15 March 1994, when, on the advice of his doctor, he took up consuming DDW. In two months the patient gained 4 kg. According to the X-ray performed in July, the size of the tumor had not changed compared to the state observed 2 years earlier. The patient’s asphyxia stopped and he became physically active again. The examination of January 1995 verified the stagnation of the tumor, while bronchoscopy executed in June described cicatrisation in the tumor area. After this, the patient was in good physical condition and in May 1996 an X-ray scan verified regression. The patient stopped the consumption of DDW in good general condition in August 1996. From January 1997 a renewed deterioration followed and in May 1999 the patient complained of pain in the operation area. Physically he was active and his weight stable. Seven years have elapsed since the diagnosis and the exploratory operation and according to the X-ray image, the tumor has encysted.
Male patient (72); on DDW from 12-05-1993
The weakened patient had a relatively small (1 cm) tumor in the upper left lobe of the lung, near the artery wall, verified by both X-ray and endoscopy. After the first month of DDW consumption, the tumor showed minimal growth but by January no growth could be verified. The patient, who had up till then been confined to bed, was able to get up. His physical condition improved and he was able to walk for hours. The patient had been consuming DDW continuously until August 1995; later, in April and October 1996 and October 1997 he repeated the cure. According to medical reports of April 1996, the tumor had encysted. Because of his hemophilia, the patient was given no conventional treatment. According to information of October 1997, the patient’s condition was stable, although 4 years earlier doctors had defined his life expectancy as only several weeks.
Male patient (47); on DDW from 01-10-1994
The patient had been treated from May 1993 onwards with inoperable lung cancer of an epithelial origin. Until the beginning of the DDW cure, the patient lost 15 kg; the size of the tumor stagnated. Later a minimal regression and, according to the December 1993 examination, progression was verified. Because of the progression, from January 1994, a change in the protocol was introduced. The patient tolerated the treatment well; his state was characterised by stagnation and an occasional decrease of atelectasia (August 1994). He received his last treatment in September 1994. The examination in December 1994, performed 3 months after the last cytostatic treatment when DDW was the only kind of treatment, described a “large-scale regression” that continued according to the examination results of March 1995. Progression again was detectable in January 1996; the patient died in October 1996, three and a half years after the diagnosis of the illness. He had been consuming DDW continuously.
Female patient (54); on DDW from 02-15-1994
In January 1994, the patient was diagnosed with adenocarcinoma of the lung. One month later she began to consume DDW and consumed it continuously for 20 months, until October 1995. During this time no progression occurred. In June 1995 the tumor that had earlier been verified as being of the size of a man’s fist became smaller. The patient was in good general condition when she stopped drinking DDW. According to our information of September 1998, four and a half years after the diagnosis with lung adenocarcinoma, she was active and working. The tumor had for years been stagnating after the consumption of DDW.
Female patient (46); on DDW from 09-29-1994
In March 1994, a 4 x 5 cm tumor and one 8 cm in size, of a mixed histological type (planocellular + anaplastic adenocarcinoma) was diagnosed. The beginning of the DDW therapy coincided with a change in the protocol, thus the 50 percent decrease in the volume of the tumor experienced two weeks later can be attributed to the joint effect of the two kinds of treatment. Cytostatic treatment ended in February 1995. By March the patient had no more asphyxiation, her general condition was good, and by June she gained 12-14 kg of body weight. A renewed progression was verified in August; the patient died in March 1996, two years after the diagnosis.
Female patient (61); on DDW from 11-29-1994
The patient was diagnosed with microcellular lung cancer in September 1994; cytostatic treatment began in October. The patient reacted well but tolerated the grave side-effects with difficulty. She had been consuming DDW continuously from November 1994 until October 1995; her physical state was satisfactory. She did not show up after this, but from another patient treated in the same hospital we know that she died four years after the diagnosis and 3 years after finishing the DDW therapy.
Female patient (75); on DDW from 04-18-1995
The patient was operated on in August 1993 with adenocarcinoma. The tumor was attached to the wall pleura in the apex. In the centre of segment III, a tumor the size of a walnut was found. This and the hilar lymphatic nodes were removed by lobotomy.
The Ca 19-9 tumor marker value of the patient increased from the end of 1994:
November 1994: 54.8 ng/ml
January 1995: 54.3 ng/ml
February 1995: 74.9 ng/ml
In the first three months of consuming DDW the patient lost 5 kg, and the tumor marker further increased.
July 1995: 86.1 ng/ml
After the increase of the DDW dose, from December 1995 the tumor marker values were as follows:
December 1995: 60.8 ng/ml
March 1996: 45.4 ng/ml
October 1996: 39.4 ng/ml
January 1997: 29.6 ng/ml
June 1997: 23.5 ng/ml
January 1998: 20.2 ng/ml
The patient has been consuming DDW for the fifth year; lives in good physical condition and without complaints six years after the operation.
Male patient (69); on DDW from 10-10-1995
In June 1994 a left side pulmonary neoplasia was verified (planocellular), which, during exploration, proved to be inoperable. The tumor infiltrated the pericardium and entwined the main arteries. Because of the size and location of the tumor, conventional treatment had to be rejected; thus, DDW was the only means of treating the patient. After a six month DDW therapy by April 1996 the patient noted improvement in his health. ESR fell from 80 to 6, the size of the tumor stagnated. The blood sugar level of the diabetic patient decreased, his dyspnoea lessened, the accumulated residues cleared up from the left lung, and the patient was able to return to his work as a physician. In the fall of 1997, the patient felt well enough to undertake a journey abroad. His state was stable until June 1998, when a slow tumor growth was observed. In July 1998 the patient underwent a myocardial infarction and had dyspnea even at rest. Heart complaints were stabilized with medication, and his tumor showed minimal growth only, despite the fact that following the heart attack he stopped the consumption of DDW, and restarted in January 1999 only. In June 1999 the patient had no dyspnea when resting and X-ray showed a moderate progression. He has been consuming DDW for 4 years now, with only one break in the meantime. The patient regularly coughs up a considerable amount of secretion.
COLORECTAL
Note: With this tumor type, in the case of distant metastases, we “only” succeeded in significantly enhancing survival. This tumor type reacts to deuterium depletion very slowly, and 90-ppm DDW was not of a sufficiently low D-content to be able to eliminate larger metastases in the liver. It would be of great significance if the patient consumed DDW continuously for 1–1.5 years after colon-rectum surgery, as this approach may prevent the appearance of distant metastases. With this tumor type, as it is with the presence of distant metastases, it is advisable to start DDW treatment with water of 75–62.5 ppm D-content.
Female patient (55); on DDW from 11-03-1993
Sonography conducted in October 1993 verified 5 liver metastases originating from the tumor of the rectum. The patient complained of severe pain in the liver area, which stopped within days after DDW consumption. In February 1994, the patient, who had not been consuming DDW for a week, reported a reappearance of pain which stopped again after the renewed consumption of DDW. The patient’s state was stable and she was active during 1994 and in early 1995. She stopped consuming DDW in March 1995, and died in July 1995, 21 months after the verification of metastases in the liver.
Male patient (65); on DDW from 10-10-1994
In September 1994, originating from a colon tumor, a 3–6 cm multiplex metastasis was verified in the liver. Tumor marker values were measured immediately before the beginning of DDW consumption (10-06-1994), then four months later (02-20-1995).
The values were as follows:
CEA: 959 ng/ml 189.7 ng/ml
CA-50: 998 U/ml 195.8 U/ml
Ca-242: 3069 U/ml 324.6 U/ml
The patient had been consuming DDW until his death in July 1996.
The patient survived 22 months after the diagnosis in September 1994.
Male patient (58); on DDW from 02-07-1995
In February 1995, a 60-cm section of the colon was removed in surgery. In the liver, 5–6 metastases were found, one of which was the size of an apple. The patient was given 5FU + Leukovorin treatment. According to an examination in March – after the consumption of DDW for a month – the two kidney cysts were not detectable and by May the patient had gained 6 kg. CT and sonography in October verified stagnation and the presence of calcified spots in the liver. CT scan conducted in August 1996 also verified stagnation. From October occasional diarrhea occurred, followed by significant deterioration in health. The patient died in May 1997, 27 months after the diagnosis of the illness and the appearance of metastases in the liver.
Note: With this tumor type, in the case of distant metastases we “only” succeeded in significantly enhancing survival. This tumor type reacts to deuterium depletion very slowly, and 90-ppm DDW was not of a sufficiently low D-content to be able to eliminate larger metastases in the liver. It would be of great significance if the patient consumed DDW continuously for 1–1.5 years after colon-rectum surgery, as a cure could prevent the appearance of distant metastases. With this tumor type and in the presence of distant metastases, it is advisable to start DDW treatment with water of 75–62.5 ppm D-content.
PROSTATE
Note: In the case of prostate tumor it is of great significance that by measuring PSA value, the potentially tumorous patient population can be defined. Based on our results so far, we are of the opinion that if we are able to diagnose the illness in its early phase, with the application of DDW this tumor type can be cured with great efficacy without the need for drug treatment throughout the patient’s whole life. It would be of great economic significance to test the male population above 50–60 for PSA value and to treat cancer patients with DDW. For the time being, the cheap test is followed by very expensive treatment (approx. USD 2000-3000/year/patient) which, in the majority of cases lasts throughout the entire life of the patient. The application of DDW would make the treatment followed by cheap scanning accessible to everyone.
Male patient (61 years) on DDW from 04-15-2003
The patient’s prostate cancer was diagnosed in March 2002 after permanently existing bone pain for a year (size of prostate was double of normal, having a cartilage hardness touch, the value of PSA was more than 1.000 ng/mL). Prostate cancer was diagnosed by biopsy and a bone metastasis by scintigraphy. After the diagnosis the patient was given the usual conventional treatments (Estracyt, Anandron) following the diagnosis. The patient started consuming DDW one year after the diagnosis, in March 2003. Three months later the bone scintigraphy verified regression in the bone, one year later the PSA-value decreased to 0.15 ng/mL. The intensity of bone metastases decreased after two years consumption of DDW. Patient suspended the consumption of DDW for 6 months in March 2005. In the fall of 2005 the PSA-value increased to 2.7 ng/mL and it showed an increasing tendency even after patient restarted consuming DDW (PSA-values: November 2005: 3.6 ng/mL; January 2006: 4.34 ng/mL), but after additional two months the tendency turned back (March 2006: 2.6 ng/mL, May: 1.07 ng/mL, June: 0.25 ng/mL). The PSA-value was 0.00 ng/mL in September 2007, 5 years after the diagnosis of prostate cancer, the patient is asymptomatic, bone pains have not occured since 2004.
Male patient (71 years) on DDW from 10-25-2005
A PSA-value of 540 ng/mL was measured in the patient in October 2005 and bone scintigraphy verified multiple bone metastases. Transurethal resection of the prostate (TURP) was performed after the biopsy, then a medication was started (Anandron, Suprefact depot, Zometa). Three months later the PSA value decreased to 2.79 ng/mL. Eight months after the diagnosis (June 2006) examinations verified a definite regression in the bone, that showed further improvement in April 2007. The PSA-value was 1.8 ng/mL in August 2007 and the patient was asymptomatic.
Male patient (65); on DDW from 10-30-1992
The patient was diagnosed with inoperable prostate tumor in October 1992. After the beginning of the cure he noted an improvement in urination problems and the PSA value decreased even prior to the start of the Fugerel treatment. After one month the tumor became impalpable and also operable, but the patient (a physician by profession) refused to undergo surgery. After drinking DDW for a year, the patient has been free of complaints for seven years.
Male patient (66); on DDW from 12-01-1994
In September 1994 the tumor of the prostate caused total obstruction and metastases in the lymphatic glands. In October the PSA value was 83.4 ng/ml. Following DDW consumption, urination problems stopped within a short time. Two weeks after the start of the DDW cure, blood samples revealed a 0.99 ng/ml PSA value. This, however, was thought to be erroneous, therefore two weeks later it was repeated, and showed a value of 0.6 ng/ml. This value decreased by March 1995 to 0.23 ng/ml, whereas values measured in June 1996 and January 1997 were below the traceable level. The patient had, for the first time, been drinking DDW continuously for 9 months, and repeated therapy for 2–3 months in 1996.
OVARIAN
Note: It is a well-known fact that patients with ovarian tumors have a very poor prognosis. In spite of this, however, according to our experience it can be well treated with D-depletion. We would like to stress that between prognoses based on our present knowledge and the efficacy of DDW there is no strict correlation. This means that tumor types that seem hopeless from the traditional point of view may react well to DDW treatment. In the case of tumors of the ovary we wish to highlight that in some cases a relapse may occur even after remission for several years if the patient stops consuming DDW.
Female patient (45); on DDW from 02-1993
The patient was operated on with tumor of the ovary in 1993. Following surgery, her tests were negative; she had a good appetite, gained 4 kg and was active and working. She had been consuming DDW continuously between February 1993 and November 1994, when, with regard to the long symptom-free period, she stopped the cure. Results of examinations in December 1994 were negative, but two months later complaints in the abdomen appeared. In February 1995, a repeated operation took place. After this the patient resumed the consumption of DDW. It is to this that we attribute that, despite the positive cytological result, sonography turned out to be negative again. In April 1996 recidiva could be verified. The patient died in November 1997 after a long struggle, nearly three years after the first relapse. (After this, we did not recommend to other patients tumor of the ovary to stop drinking DDW even after a post-operative two-year-long symptom-free period.)
Female patient (52); on DDW from 04-04-1996
The patient was diagnosed with tumor of the ovary in the summer of 1995 which, histologically, proved to be a highly differentiated adenocarcinoma. The uterus and the omentum were also affected. After surgery the patient was given a series of 8 cytostatic treatments (Carboplatin, Cysplatin) that ended in March 1996. She began to consume DDW after the completion of conventional treatment and has been drinking it for 40 months continuously – she is active and symptom-free.
Note: It is a well-known fact that patients with ovarian tumors have a very poor prognosis. In spite of this, however, according to our experience it can be well treated with D-depletion. We would like to stress that between prognoses based on our present knowledge and the efficacy of DDW there is no strict correlation. This means that tumor types that seem hopeless from the traditional point of view may react well to DDW treatment. In the case of tumors of the ovary we wish to highlight that in some cases a relapse may occur even after remission for several years if the patient stops consuming DDW.
CERVICAL
Female patient (47); on DDW from 11-22-1993
The patient was diagnosed in November 1993 with an inoperable cervical tumor that was entwined with the ovaries. Beginning in March 1994, when the patient started to consume DDW, her state improved continuously. She gained weight and the tumor in the cervix was no longer detectable. By June the earlier stricture of the intestines also disappeared and the patient was in good general mood. Starting in November 1994 the patient began to consume water of a less depleted D-content. Results of examinations in February 1995 verified significant progression. We were able to follow the patient for another five months, during which time she did not consume DDW in sufficient quantities, upon which there was a slow regression in her state. This case demonstrates well the connection between the consumption of DDW and the behavior of the tumor, as well as the importance of establishing and maintaining the right dose.
TOUNGE
Female patient (56); on DDW from 07-12-1992
The patient underwent the first surgery in March 1989 with a tumor of the tongue which had been present for a year. In 1990, the tumor receded and the patient was given repeated treatment. At the end of 1992, a relapse occurred again and it was then that the patient began to consume DDW. From that time on, the size of the tumor decreased, and biopsy performed in March 1993 did not verify tumorous tissue in the sample. The patient had been consuming DDW continuously during the year 1993, and made a break in January 1994. Subsequently there was a significant progression of the illness, and another operation became necessary in August 1994. DDW consumption was regular from June 1994 on. In February 1997, another biopsy was performed which again proved to be positive. By increasing the DDW dose, the size of the newly appeared nodes decreased, and their texture became softer. A more significant progression was experienced in the spring of 1998 only, when X-ray verified lung metastasis. Due to the increased dose the patient coughed up slimy secretions, the tumor in her mouth got softer, the size of the tumor near the esophagus decreased, and the tumor at the ear was no longer sensitive. The patient survived another year, and died in the spring of 1999. Ten years had elapsed since the first operation. In the first three years, prior to DDW consumption, there were three relapses. We suppose that by a continuous DDW consumption, relapses of such an extent would not have occurred. The next case serves as a good example of the above.
Female patient (63); on DDW from 07-13-1993
The patient had received three operations before June 1993 with renewed tumors of the oral cavity. Then, as the patient refused to consent to the partial elimination of the jaw, she was given a full dose of radiation. At that time she began to drink DDW. By August 1993 the wound under the tongue had healed, the tumor on the chin softened and by September the tumor on the neck disappeared. From a medical point of view the years 1994, 1995, 1996, and the first nine months of 1997 went by uneventfully. Then a wound made by an apricot pit would not heal. The patient was given two cytostatic treatments in November 1997, and the third was skipped because the wound had by then healed completely. The patient, by sustaining her good quality of life is in excellent physical condition and has been consuming DDW for the sixth year.
MELANOMA
Note: We wish to stress that despite the two successful examples mentioned below, melanoma belongs to the type of tumors that react very poorly and can be treated with great difficulty only. We could not achieve any success in cases when newer metastases appeared weekly. This observation of ours is in accordance with the in vitro examinations, according to which the melanoma cell line got adapted to the culture medium of lower D-content within 6 hours, while with prostate and breast cell lines inhibition was traceable for 24–48 hours. Thus, from the aspect of dosage, in the case of this tumor type the dose must be increased, i.e. D-level decreased in the body, within a time shorter than usual.
Male patient (51); on DDW from 11-17-1994
In July 1994, the patient had a Clark III melanoma removed. The tumor started from a mole on the left side of the abdomen. In August of the same year block dissection was performed in the left armpit. Following this, the patient was given DTIC and Interferon treatment. He had been consuming DDW regularly since the above date and was symptom-free in 1995, 1996, and 1997. During this time a single operation was performed when, in May 1996, a lymphatic node that had been in the armpit for one and a half years but showed no growth was removed. The microscopic description of the removed node contains the following: “… the bulk of the substance is occupied by tumor tissue forming contiguous fields… Frequent dividing formations. Necroses in the substance of the tumor. The tumor is surrounded by a thick fibrous case; the excision does not reveal the extension of the tumor into the adipose tissue.”
With regard to the long symptom-free period, we suggested a break in consuming DDW after more than 3 years, from the beginning of 1998. One and a half months after the suspension of the consumption of DDW, a lump appeared on the breast of the patient, after which he died without having consumed DDW, in March 1999.
Male patient (46); on DDW from 12-20-1994
The patient had first been operated on with melanoma malignum. Later, in April 1992, lymphatic nodes were removed from the armpit, followed by further surgery and DTIC treatment in the spring of 1994. By the fall, metastases appeared behind the ear and also in the liver; this was followed by Intron A treatment. According to the CT scan made one month after the start of the DDW therapy, two earlier liver metastases could not be verified, two became smaller and one remained unchanged. Further examinations (March, June, December 1996; February, December 1998) described gradual regression of the liver metastases, while, according to the April 1999 CT scan: “The formerly described small residual lesions are not traceable. Unanimously circumscribed formation is not verifiable by CT scanning.” The patient has, since the verification of liver metastases, for the fifth year been active and working.
BLOOD CANCERS
Note: DDW can, with great efficacy, be used to treat oncological problems connected to hematopoiesis. The consumption of DDW significantly enhances the efficacy of conventional treatment and increases the chances to avoid relapse.
Male patient (62); CLL; on DDW from 01-16-1996
The patient was diagnosed with B-cellular CLL in 1992. From the end of 1995 on, originating from his basic condition, an increasing leukocyte-count, anemia, and thrombocytopenia occurred. The patient was treated with concentrates of erythrocytes and thrombocytes. According to the CT scan, on both apexes of the lung residual fascicles were verified, as well as several lymphatic nodes of 1.5–2 cm in the mediastinum. The liver and the spleen were considerably enlarged; the mesentery contained partly confluent lymphatic nodes. The disease was progressing despite conventional treatment. The patient was weak, mostly bed-ridden, and was constantly losing weight (69 kg). He started consuming DDW in January 1996. In the following two months, transfusion was given less frequently; later, on the basis of his blood-count results, the patient did not need transfusion at all. He regained strength, and after four months the lymphatic nodes in the neck were not palpable. By the end of the year, abdominal complaints appeared. In January 1997, several enlarged lymphatic nodes palpable also through the wall of the abdomen were removed surgically. In the spring of 1998, further swollen nodes were found in the armpits. The patient had been drinking DDW for 3 months. After one year, in May 1999, the patient’s weight was 80 kg, no swollen lymphatic nodes were palpable, and the patient was in good physical condition.
Male patient (65); on DDW from 11-01-1994
The patient was diagnosed with myeloma multiplex in September 1994. Prior to this, in March, he had pathologically broken a rib. Cytostatic treatment had been begun two months prior to the start of the DDW cure. After two months of consumption, by January 1995, the patient had gained 5 kg. In March, electrophoresis verified significant improvement, and after a further two months no pathological deviation was shown. The patient was given the last treatment of the series in July. In September 1996, electrophoresis and blood count were found to be in order; in January 1996 blood levels were normal, and bone scintigraphy could not prove earlier thickenings. Routine examinations in September were also negative. In October 1996, the patient took a hot bath cure in Hévíz. By the end of which he felt unwell, and had pain between the ribs. In November 1996, a new treatment began. By March 1997, a tumor of a considerable size appeared on the sternum. The tumor was in regression in May, appeared again in August, and metastases appeared between the thoracic vertebrae. The patient was continuously consuming DDW, with suspension for some months only. Due to conventional DDW treatment, the patient survived a further two years and died 4 and a half years after the diagnosis.
Male patient (26); AML; on DDW from 01-10-1995
In September 1992, following a feverish condition, hypertrophy of the lymphoid nodes was reported. With knowledge of the histological diagnosis (Hodgkin lymphoma), first ABVD, then, from February 1994, COPP treatment was given. In June 1994, examinations verified AML M4. After three doses, in October 1994, the patient refused further chemotherapy. According to blood counts of 3 and 10 January 1995, the number of blastoid cells increased in the peripheries. The patient started DDW consumption on 10 January 1995, and the blood count of 31 January could not verify the presence of blastoid cells. The patient had been drinking DDW regularly till March 1997; during this time all the control examinations proved to be negative. For several months from January 1998, he had been consuming DDW as a precaution. His results have been negative for more than four years.
LIVER
Male patient (66); on DDW from 11-07-1994
A malignant tumor originating in the connective tissue of the liver had been discovered in 1985. Until the start of the DDW cure, several operations aimed at decreasing the tumor size were made, along with one closing the blood vessels in order to block the blood supply of the tumor. In May 1994, because of gastric hemorrhage caused by the breakthrough of the tumor, gastrotomy and an operation to join the stomach with the intestines were performed. Because of jaundice and the fall of the patients blood sugar level, the patient lost consciousness on several occasions. The patient was hospitalized in October 1994 because of extreme physical deterioration, in a practically hopeless state. Sonography in November recorded a tumor of 17 x 21 cm in size. Following the consumption of DDW, the patient regained appetite, gained 3.5 kg weight and was able to walk. He was discharged from hospital in November. Jaundice decreased, verified also by laboratory results, and high enzyme values caused by the tumor fell.
In February 1995, sonography verified a tumor of 16 x 14 cm. One year after the beginning of the DDW cure, jaundice almost totally disappeared, and the improvement of gall flow was proven by the fact that the color of the stool, which had for years been like clay, became normal again. A significant deterioration of the patient’s state occurred in November-December, after which he was unable to regularly consume DDW. The patient died on 27 November, 1995. The significant improvement of the patient’s state from November 1994 on lasted for a year and can be attributed to DDW consumption only, as the patient was not given any other treatment.
